For example, increasing numbers of fibrate trials have addressed fenofibrate intervention and event lowering in diabetes (FIELD) and action to control cardiovascular risk in diabetes (ACCORD), and have revealed that activation of PPARα by fibrates has rarely reduced cardiovascular disease (CV) risk [141] and has also failed to meet the criteria for controlling chronic inflammatory diseases [142]. This evidence concerns the gene PPARA and diabetes mellitus.